Advocacy groups are urging regulators to launch a bold anticompetition probe into Big Pharma’s moves after Brexit, accusing the industry of manipulating the market and driving prices sky-high. This call highlights growing concerns over pharmaceutical practices in the evolving post-Brexit landscape